Sosei Group Corp. | Ownership
Companies that own Sosei Group Corp.
JPMorgan Asset Management (Japan) Ltd.
3,935,500
5.16%
1,762,700
0.44%
08/31/2018
Taiyo Pacific Partners LP
2,997,200
3.93%
1,905,600
5.59%
05/25/2018
BlackRock Fund Advisors
925,500
1.21%
0
0%
09/06/2018
Shiozumi Asset Management Co. Ltd.
900,000
1.18%
-180,000
0.95%
07/31/2018
Taiyo Fund Management LLC
825,200
1.08%
825,200
6.44%
05/25/2018
Matthews International Capital Management LLC
698,800
0.92%
2,400
0.03%
06/29/2018
ERIM LLP
558,800
0.73%
204,800
3.6%
12/31/2017
GO ETF Solutions LLP
296,840
0.39%
264,444
0.21%
02/28/2018
RBC Investment Management (Asia) Ltd.
252,000
0.33%
52,000
0.15%
12/31/2017
Invesco Asset Management Ltd.
248,400
0.33%
-490,800
0.01%
03/29/2018
| Address |
PMO Hanzomon, 11/F
Tokyo Tokyo 102
Japan
|
|
Employees
|
- |
| Website |
http://www.sosei.com |
| Updated |
07/08/2019 |
| Sosei Group Corp. engages in the discovery, design, and development of medicines targeting G protein-coupled receptors (GPCRs). Its proprietary StaR (Stabilised Receptor) technology and structure-based drug design (SBDD) platform enables development of drugs for highly validated, yet historically undruggable or challenging GPCRs. The company has multiple programs targeting Alzheimer's disease, schizophrenia, immuno-oncology, migraine, metabolic disease and other rare and specialty indications. |
